Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children

JAMA

Volumn 309, Issue 17, 2013, Pages 1803-1809

  Lowenthal, Elizabeth D ^a,b,c   Ellenberg, Jonas H ^a   Machine, Edwin ^d,e   Sagdeo, Aditi ^a   Boiditswe, Sefelani ^d   Steenhoff, Andrew P ^a,b,c   Rutstein, Richard ^a,b   Anabwani, Gabriel ^d,e   Gross, Robert ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c BOTSWANA UPENN PARTNERSHIP   (Botswana)

^d Princess Marina Hospital   (Botswana)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; STAVUDINE; TUBERCULOSTATIC AGENT; VIRUS RNA; ZIDOVUDINE; ANTIRETROVIRUS AGENT; BENZOXAZINE DERIVATIVE;

ADOLESCENT; ANTIVIRAL THERAPY; ARTICLE; BOTSWANA; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; NUTRITIONAL STATUS; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RNA ANALYSIS; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT OUTCOME; TUBERCULOSIS; VIROLOGICAL FAILURE; VIRUS INHIBITION; VIRUS LOAD; BLOOD; DRUG COMBINATION; REGRESSION ANALYSIS; TREATMENT FAILURE;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; BENZOXAZINES; BOTSWANA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

MLCS; MLOWN;

EID: 84877139214     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.3710     Document Type: Article

References (31)

1. UNAIDS. AIDS epidemic update 2009. http://data.unaids.org/pub/Report/ 2009/JC1700-Epi-Update-2009-en.pdf. Accessed November 21, 2010.
2. UNICEF. Children and AIDS: fifth stocktaking report, 2010. http://www.unicef.org/publications/files/Children-and-AIDS-Fifth-Stocktaking- Report-2010-EN.pdf. Accessibility verified March 28, 2013.
3. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298(16):1888-1899. (Pubitemid 350005233)
4. Little K, Thorne C, Luo C, et al. Disease progression in children with vertically-acquired HIV infection in sub-Saharan Africa: reviewing the need for HIV treatment. Curr HIV Res. 2007;5(2):139-153. (Pubitemid 46488193)
5. World Health Organization. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization Press; 2010.
6. Nachega JB, Hislop M, Dowdy DW, et al. Efavirenz versus nevirapine-based initial treatment of HIV infection. AIDS. 2008;22(16):2117-2125.
7. Hartmann M, Witte S, Brust J, et al. Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort). Int J STD AIDS. 2005;16(6):404-409. (Pubitemid 40868375)
8. Lapphra K, Vanprapar N, Chearskul S, et al. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children. Int J Infect Dis. 2008;12(6):e33-e38.
9. Patel AK, Pujari S, Patel K, et al. Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients. J Assoc Physicians India. 2006;54:915-918.
10. Mbuagbaw LC, Irlam JH, Spaulding A, et al. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviralnaïve individuals. Cochrane Database Syst Rev. 2010;(12):CD004246.
11. Southern African Journal of HIV Medicine. Guidelines for antiretroviral therapy in children-November 2009 version. http://www.sahivsoc.org/upload/ documents/guidelines-Guidelines-for-Antiretroviral-Therapy-in-Children-November- 2009.pdf. Accessed March 16, 2013.
12. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. http://aidsinfo.nih.gov/contentfiles/lvguidelines/ pediatricguidelines.pdf. Accessed March 16, 2013.
13. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46(2):187-193. (Pubitemid 47482614)
14. Botswana Ministry of Health. Botswana National HIV/AIDS Treatment Guidelines. Gaborone: Botswana Ministry of Health; 2008.
15. Lowenthal ED, Anabwani GM, Jibril HB, et al. Botswana-Baylor Children's Clinical Centre of Excellence. South Afr J HIV Med. 2005;6(2):42-46.
16. Tolle M, Howard L, Kirk B, et al. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana. J Int Assoc Physicians AIDS Care (Chic). 2012;11(4):260-268.
17. Botswana Ministry of Health. Botswana Guidelines on Anti-Retroviral Treatment. Gaborone: Botswana Ministry of Health; 2005.
18. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep. 1994;43(RR-12):1-10.
19. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-2281.
20. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 pt 2):757-763. (Pubitemid 27446562)
21. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239-241.
22. Carlin J, Galati J, Royston P. A new framework for managing and analyzing multiply imputed data in Stata. Stata J. 2008;8(1):49-67.
23. World Health Organization. Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011. http://www.who.int/hiv/pub/progress-report2011/en/. Accessibility verified March 28, 2013.
24. Uthman O, Mofenson LM, Nachega JB. Safety and effectiveness of efavirenz versus nevirapine-based regimens in resource-limited settings. AIDS. 2012;26(5):639-641.
25. Ouattara EN, Anglaret X, Wong AY, et al. Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age. AIDS. 2012;26(5):625-634.
26. Manosuthi W, Sungkanuparph S, Tantanathip P, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin. Clin Infect Dis. 2009;48(12):1752-1759.
27. Walters E, Cotton MF, Rabie H, et al. Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on antiretroviral therapy. BMC Pediatr. 2008;8:1.
28. de Onis M, Onyango AW, Borghi E, et al. Comparison of the World Health Organization (WHO)Child Growth Standards and the National Center for Health Statistics/WHO International Growth Reference: implications for child health programmes. Public Health Nutr. 2006;9(7):942-947. (Pubitemid 46211797)
29. Geretti AM. HIV-1 subtypes. Curr Opin Infect Dis. 2006;19(1):1-7.
30. Easterbrook PJ, Smith M, Mullen J, et al. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc. 2010;13:4.
31. Baeten JM, Chohan B, Lavreys L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis. 2007;195(8):1177-1180. (Pubitemid 46543449)